VEGF-C gene therapy - Herantis Pharma

Drug Profile

VEGF-C gene therapy - Herantis Pharma

Alternative Names: Ad-VEGF-C - Herantis Pharma; Lymfactin

Latest Information Update: 25 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Helsinki
  • Developer Herantis Pharma
  • Class Gene therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor C expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Lymphoedema

Most Recent Events

  • 19 Oct 2017 Herantis Pharma plans a phase II study for Lymphoedema in 2018
  • 22 Jun 2017 Herantis plans to submit an application to regulatory authorities for a phase II randomised, placebo-controlled clinical trial by the end of 2017
  • 23 Jan 2017 Herantis Pharma has patent protection for VEGF-C gene therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top